---
figid: PMC4743050__nihms-729689-f0006
figlink: /pmc/articles/PMC4743050/figure/F6/
number: Figure 6
caption: Second generation RAF inhibitors such as vemurafenib and dabrafenib are BRAF-selective
  and cause paradoxical activation of ERK (panel (a)). The inhibitor-blocked BRAF
  forms a heterodimer with active CRAF and complexes with activated RAS. MEK inhibitors
  transiently block ERK activation. Since high ERK activation can be deleterious for
  cell proliferation, ERK activation stimulates negative feedback mechanisms that
  dampen upstream signaling through the pathway (panel (b)). Kinome reprogramming
  results in rewiring of the signaling networks to increase flux through non-RAF-MEK-ERK
  pathways such as PI3K-AKT-mTOR.
pmcid: PMC4743050
papertitle: 'Targeting RAS-mutant cancers: is ERK the key?.'
reftext: Meagan B. Ryan, et al. Trends Cancer. ;1(3):183-198.
pmc_ranked_result_index: '89924'
pathway_score: 0.9687598
filename: nihms-729689-f0006.jpg
figtitle: 'Targeting RAS-mutant cancers: is ERK the key?'
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4743050__nihms-729689-f0006.html
  '@type': Dataset
  description: Second generation RAF inhibitors such as vemurafenib and dabrafenib
    are BRAF-selective and cause paradoxical activation of ERK (panel (a)). The inhibitor-blocked
    BRAF forms a heterodimer with active CRAF and complexes with activated RAS. MEK
    inhibitors transiently block ERK activation. Since high ERK activation can be
    deleterious for cell proliferation, ERK activation stimulates negative feedback
    mechanisms that dampen upstream signaling through the pathway (panel (b)). Kinome
    reprogramming results in rewiring of the signaling networks to increase flux through
    non-RAF-MEK-ERK pathways such as PI3K-AKT-mTOR.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - RAF1
  - BRAF
  - MAP2K2
  - NRAS
  - PIK3R3
  - MAP2K1
  - AKT3
  - MAPK3
  - HRAS
  - KRAS
  - MAPK1
  - PIK3R6
  - PIK3CD
  - PIK3CB
  - MTOR
  - PIK3CG
  - PIK3R4
  - PIK3R5
  - AKT2
  - AKT1
  - PIK3CA
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: BRAF
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
chemicals:
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
---
